EORTC, BOOG
F. Cardoso (EORTC), C.P. Schröder, J. Martens, C van Asperen (BOOG)
A.E. van Leeuwen-Stok, N.H. Dijkstra
BOOG Study Center Postbus 9236 1006 AE Amsterdam tel 020 346 2547 fax 020 346 2597 email info@boogstudycenter.nl
Funding by Pink Ribbon
Retrospective dataregistration
To perform a large international joint retrospective analysis of clinical and biological data of male BC patients treated in the last 20 years. To create a database of patient characteristics, disease features, treatments received and clinical outcomes of a large series of men diagnosed with BC over the last 20 years in centers in Europe, America and third countries. To perform a central pathological review of the correspondent large series of male BC tumors to determine their biological characteristics and identify relevant prognostic and predictive markers. This study will provide important information regarding male BC and set the scene for a second phase which is a prospective, international, multicenter, registry of male BC with concomitant material collection which will enable us to decide if a clinical trial could be launched for male BC patients.
Primary enpoint:
Males with histologically proven invasive breast carcinoma diagnosed since 1990 to date. Concomitant DCIS or LCIS are allowed if invasive cancer is present. A FFPE tissue sample from primary tumor (e.g. biopsy or surgery) is mandatory for enrollment of the patient and must be available for central pathology review. The availability of fresh frozen samples is optional. The study will accept all stages of disease (e.g. early BC, locally advanced and metastatic disease) independent of the treatment received.
